Journal of Nephrology

, Volume 27, Issue 6, pp 681–688

Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients

  • Adriana M. Hung
  • Chutatip Limkunakul
  • Jenny S. Placido
  • Edward D. Siew
  • Charles D. Ellis
  • Ayumi Shintani
  • Talat Alp Ikizler
Original Article
  • 126 Downloads

Abstract

Background

Adiponectin, an adipose tissue derived hormone, is known to have insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties in the general population. Adiponectin secretion is suppressed by systemic inflammation, a highly prevalent condition in maintenance hemodialysis (MHD) patients. We evaluated whether short-term administration of interleukin 1 receptor antagonist (IL-1ra) improves adiponectin levels and insulin sensitivity in MHD patients.

Methods

Ad hoc analysis was performed on a pilot randomized placebo-controlled trial of the administration of IL-1ra in chronically inflamed MHD patients. Twenty-two patients were randomly assigned to receive 100 mg of IL-1ra or placebo (1:1) for 4 weeks, and 14 completed the trial. ANCOVA was used to compare percent change from baseline to 4 weeks. The primary outcome was percent change in adiponectin and the secondary outcomes were changes in leptin, homeostatic model assessment of insulin resistance (HOMA-IR) and the leptin-to-adiponectin ratio (LAR).

Results

Patients’ mean age was 49 ± 13 years, and 71 % were males. At baseline, the median values for adiponectin, leptin, LAR and HOMA-IR were 11.5 μg/ml [interquartile range (IQR) 9, 28.5], 17.8 ng/ml (3.9, 50.0), 2.20 (0.13, 3.98), and 2.8 (2.0, 3.6), respectively. IL-1ra administration resulted in a mean percent increase in serum adiponectin of 22 % vs. 14 % decrease in the placebo arm (p = 0.003). Leptin, LAR or HOMA-IR levels did not change in either arm.

Conclusions

Short-term administration of IL-1ra significantly increased adiponectin levels among prevalent MHD patients. The intervention did not impact insulin sensitivity parameters. Studies of longer duration and larger sample size are needed to further evaluate the potential effect of anti-inflammatory interventions on metabolic markers and insulin sensitivity in MHD patients.

Keywords

Anakinra Interleukin 1-ra Adiponectin Dialysis Insulin resistance 

References

  1. 1.
    Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W et al (2012) United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 59(A7):e1–420Google Scholar
  2. 2.
    Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238–248PubMedCrossRefGoogle Scholar
  3. 3.
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339(9):584–590PubMedCrossRefGoogle Scholar
  4. 4.
    Cano NJ, Fouque D, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, Combe C, Laville M, Leverve XM (2007) Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 18(9):2583–2591PubMedCrossRefGoogle Scholar
  5. 5.
    Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298(10):1163–1170PubMedCrossRefGoogle Scholar
  6. 6.
    Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89(6):2548–2556PubMedCrossRefGoogle Scholar
  7. 7.
    Nanayakkara PW, Le Poole CY, Fouque D, van Guldener C, Stehouwer CD, Smulders YM, van Ittersum FJ, Siegert CE, Drai J, Kostense PJ et al (2009) Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3–5 chronic kidney disease. Clin Nephrol 72(1):21–30PubMedCrossRefGoogle Scholar
  8. 8.
    Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P (1998) Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 54(4):1267–1275PubMedCrossRefGoogle Scholar
  9. 9.
    Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M et al (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102(11):1296–1301PubMedCrossRefGoogle Scholar
  10. 10.
    Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26(3):439–451PubMedCrossRefGoogle Scholar
  11. 11.
    Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116(7):1784–1792PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ et al (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115(11):1408–1416PubMedCrossRefGoogle Scholar
  13. 13.
    Ahima RS (2008) Linking adiponectin to proteinuria. J Clin Invest 118(5):1619–1622PubMedCentralPubMedGoogle Scholar
  14. 14.
    Fantuzzi G (2008) Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 121(2):326–330PubMedCrossRefGoogle Scholar
  15. 15.
    Fantuzzi G (2009) Adiponectin and inflammation. Am J Physiol Endocrinol Metab 296(2):E397PubMedCrossRefGoogle Scholar
  16. 16.
    Dinarello CA (1992) Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. Kidney Int Suppl 38:S68–S77PubMedGoogle Scholar
  17. 17.
    Shaldon S, Dinarello CA, Koch KM, Lonnemann G, Bingel M, Granolleras C, Deschodt G, Branger B, Oules R, Fourcade J (1988) Interleukin-1 and dialysis. Adv Nephrol Necker Hosp 17:423–434PubMedGoogle Scholar
  18. 18.
    Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M, Hastings J, Socratous F, Esler M (2004) Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab 286(5):E744–E752PubMedCrossRefGoogle Scholar
  19. 19.
    Wallander M, Soderberg S, Norhammar A (2008) Leptin: a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and without previously known type 2 diabetes. Diabet Med 25(8):949–955PubMedCrossRefGoogle Scholar
  20. 20.
    Maury E, Brichard SM (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314(1):1–16PubMedCrossRefGoogle Scholar
  21. 21.
    Grisouard J, Dembinski K, Mayer D, Keller U, Muller B, Christ-Crain M (2011) Targeting AMP-activated protein kinase in adipocytes to modulate obesity-related adipokine production associated with insulin resistance and breast cancer cell proliferation. Diabetol Metab Syndr 3:16PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752PubMedCrossRefGoogle Scholar
  23. 23.
    Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K (2008) The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 149(5):2208–2218PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356(15):1517–1526PubMedCrossRefGoogle Scholar
  25. 25.
    Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA (2011) IL-1beta receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 22(3):437–442PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange A, Capeau J, Caron M (2006) Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 49(9):2162–2173PubMedCrossRefGoogle Scholar
  27. 27.
    Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B (2004) Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219(1–2):9–15PubMedCrossRefGoogle Scholar
  28. 28.
    Dinarello CA (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol 40(3):599–606PubMedCrossRefGoogle Scholar
  29. 29.
    Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K et al (2010) The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21(10):1732–1744PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, Feingold KR (1996) Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 97(9):2152–2157PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Sarraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivet DJ 3rd, Flier JS, Lowell BB, Fraker DL, Alexander HR (1997) Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 185(1):171–175PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Janik JE, Curti BD, Considine RV, Rager HC, Powers GC, Alvord WG, Smith JW 2nd, Gause BL, Kopp WC (1997) Interleukin 1 alpha increases serum leptin concentrations in humans. J Clin Endocrinol Metab 82(9):3084–3086PubMedGoogle Scholar
  33. 33.
    Fain JN (2010) Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm 2010:513948PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, Capeau J, Bastard JP (2004) Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 28(8):993–997PubMedCrossRefGoogle Scholar
  35. 35.
    Larsson H, Ahren B (1996) Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. J Clin Endocrinol Metab 81(12):4428–4432PubMedGoogle Scholar
  36. 36.
    Papaspyrou-Rao S, Schneider SH, Petersen RN, Fried SK (1997) Dexamethasone increases leptin expression in humans in vivo. J Clin Endocrinol Metab 82(5):1635–1637PubMedCrossRefGoogle Scholar
  37. 37.
    Tack CJ, Stienstra R, Joosten LA, Netea MG (2012) Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol Rev 249(1):239–252PubMedCrossRefGoogle Scholar
  38. 38.
    Hung AM, Ikizler TA (2011) Factors determining insulin resistance in chronic hemodialysis patients. Contrib Nephrol 171:127–134PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Nephrology (outside the USA) 2014

Authors and Affiliations

  • Adriana M. Hung
    • 1
    • 2
  • Chutatip Limkunakul
    • 2
  • Jenny S. Placido
    • 4
  • Edward D. Siew
    • 2
  • Charles D. Ellis
    • 2
  • Ayumi Shintani
    • 3
  • Talat Alp Ikizler
    • 1
    • 2
  1. 1.Clinical Science Research & Development Veterans AdministrationTVHSNashvilleUSA
  2. 2.Division of NephrologyVanderbilt University Medical CenterNashvilleUSA
  3. 3.BiostatisticsVanderbilt UniversityNashvilleUSA
  4. 4.Universidad San Juan BautistaCaguasUSA

Personalised recommendations